Health Care Provider Knowledge Around Shared Clinical Decision-Making Regarding HPV Vaccination of Adults Aged 27-45 Years in the United States

Background

The Advisory Committee on Immunization Practices (ACIP) recommends shared clinical decision-making (SCDM) regarding HPV vaccination for adults aged 27-45 years who are not adequately vaccinated. The objective of this survey was to understand physician knowledge, attitudes, and practices regarding HPV vaccination in this age group.

Methods

An online survey was administered in June 2021 to physicians who reported practicing internal medicine, family medicine, or obstetrics and gynecology (targeted N=250 in each practice specialty), selected randomly from potentially eligible physicians from a panel of 2 million U.S. health care providers.

Results

In total, 753 physicians participated in the survey: 33.3% practiced internal medicine, 33.1% practiced family medicine, and 33.6% practiced obstetrics/gynecology; 62.5% were male and mean physician age was 52.7 years. Despite the COVID-19 pandemic, at least a third of participating physicians in each practice specialty reported having more HPV vaccine SCDM discussions with patients aged 27-45 years in the past 12 months. While a majority of physicians (79.7%) reported being aware of the SCDM recommendation for adults in this age group, only half of physicians answered an objective knowledge question about SCDM recommendations correctly.

Conclusions

Findings suggest that there are physician knowledge gaps related to SCDM for HPV vaccination. To improve access to HPV vaccination for people most likely to benefit, increasing availability and use of decision aids to support SCDM discussions might help healthcare providers and patients jointly make the most informed decisions about HPV vaccination.

Gidengil, C., Parker, A., Markowitz, L., Gedlinske, A., Askelson, N., Petersen, C., Meites, E., Lindley, M., & Scherer, A. Health Care Provider Knowledge Around Shared Clinical Decision-Making Regarding HPV Vaccination of Adults Aged 27-45 Years in the United States. https://doi.org/10.1016/j.vaccine.2023.02.051.